The phase III KEYNOTE-355 trial investigating Keytruda in combination with chemotherapy met one of its dual primary endpoints of progression-free survival in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1 (Combined Positive Score [CPS] ≥10).
For a year before an osteosarcoma was found in her right proximal tibia, Sammy Ulloa, pushing through pain, persisted with her training as a Division I track and field and cross-country competitor.
